Mahya Aghaee (ORCID 0000-0001-9635-7298) shows a clear two-phase career: a mathematical optimization core (2016β2023) followed by a translational immunology/quantitative systems pharmacology (QSP) phase (2023β2026) at University of Florida Health . The anchor work is 'The Switch Point Algorithm' in SIAM Journal on Control and Optimization (2021, 30 citations), a first-author methods paper with W.W. Hager on solving singular/bang-bang optimal control problems with jump discontinuities . Applied extensions include PASA-based singular control in mathematical biology and an SIR model with time-varying populations where singular controls shape optimal vaccination/treatment strategies .
A first-author, gold-OA QSP paper in European Journal of Pharmaceutical Sciences (2023, 8 citations) determines optimal combination regimens for multiple myeloma with industry co-authors (Pfizer) and clinician-scientists . Recent work applies mechanistic modeling to liver transplant immune dynamics (Bulletin of Mathematical Biology, 2025) and canine glioma mRNA vaccine immunology (JITC, 2025) , plus several Neuro-Oncology conference abstracts .
Strengths: genuine methodological depth (a first-author SIAM paper is a nontrivial achievement), versatility across epidemiology, oncology, transplant immunology, and bioinformatics-driven target discovery, and strong collaboration networks (Hager, Ledzewicz, Moore, Zarrinpar). Blindspots: citation impact is modest β 47β65 total citations with h-index 4 puts the author in the early-career tier, with most impact concentrated in a single 2021 methods paper; several recent works are conference abstracts with 0 citations and no peer-reviewed full text; clinical prediction claims (e.g., 'predicts important drivers of patient outcome') await external validation; industry co-authorship (Pfizer) introduces sponsor-bias considerations; and no primary institution is verifiable in OpenAlex metadata, limiting affiliation-based checks. What would change this assessment: independent replication of the transplant/myeloma models, full papers for the abstracts, and citations of the newer translational work by third parties.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.